This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Budesonide orodispersible tablet

Updated 2 Feb 2023 | Glucocorticoid therapy


Orodispersible formulations of budesonide.

Drugs List

  • budesonide 0.5mg orodispersible tablets sugar-free
  • budesonide 1mg orodispersible tablets sugar-free
  • JORVEZA 0.5mg orodispersible tablet
  • JORVEZA 1mg orodispersible tablet
  • Therapeutic Indications


    Eosinophilic oesophagitis



    Initial dose: 2mg daily, taken as two separate even doses (morning and evening).

    The initial treatment duration is 6 weeks. This may be extended up to 12 weeks in patients who are not responding within 6 weeks.

    Maintenance dose: 1mg to 2mg daily, taken as two separate even doses (morning and evening).


    Children under 18 years
    Uncontrolled systemic infection
    Hepatic impairment
    Severe renal impairment

    Precautions and Warnings

    Family history of diabetes mellitus
    Family history of glaucoma
    Diabetes mellitus
    History of steroid-induced psychosis
    Moderate renal impairment
    Peptic ulcer
    Psychiatric disorder

    May mask symptoms or signs of infections
    Systemic corticosteroids may be needed during periods of stress
    Treatment to be initiated by specialist
    Clinical presentations of infections may be atypical
    If visual disturbances occur, perform ophthalmic evaluation
    Antibody response to vaccines may be reduced
    High doses may cause adrenal suppression/bone metabolism changes
    Patient should report worrying psychological changes esp. suicidal thoughts
    May affect results of some laboratory tests
    Advise patient not to take St John's wort concurrently
    Advise patient to avoid grapefruit products
    Advise patient to avoid exposure to measles
    Advise those on systemic corticosteroids to avoid chickenpox/H zoster

    Candidiasis of the mouth and throat should be treated with topical or systemic anti-fungal therapy, while continuing treatment with budesonide orodispersible tablets.

    Systemic effects of corticosteroids such as Cushing's syndrome, adrenal suppression, growth retardation, decreased bone mineral density, cataract, glaucoma and very rarely a wide range of psychiatric/behavioural effects may occur, particularly when prescribed at high doses and for prolonged periods.

    Corticosteroids may cause suppression of the hypothalamic pituitary adrenal axis (HPA axis) and reduce the stress response. Where patients are subject to surgery or other stresses, supplementary systemic glucocorticoid treatment is recommended.

    Pregnancy and Lactation


    Use Budesonide with caution during pregnancy.

    The manufacturer advises the use of budesonide during pregnancy should only occur when the expected benefits to mother and child outweigh the risks. It is unknown whether budesonide crosses the human placenta. The low molecular weight (about 431) and high lipid solubility predict substantial placental transfer. Administration of corticosteroids to pregnant animals may cause abnormalities of foetal development, including intra-uterine growth retardation and skeletal anomalies.


    Use Budesonide with caution during breastfeeding.

    The manufacturer advises that a decision should be made on whether to discontinued breastfeeding or to discontinue treatment for the mother, after reviewing the benefits of breastfeeding for the child and the benefits of treatment for the mother. Budesonide is excreted into breast milk, however, only minor effects are anticipated for the breast-fed child following use at the clinically recommended dose.


    Take after a meal.

    Advise patient to place the orodispersible tablet on the tip of the tongue and gently press it against the top of the mouth, where it will dissolve.

    The orodispersible tablet should not be chewed or swallowed undissolved or taken with liquid or food.

    Advise patient that there should be at least 30 minutes before eating or drinking or performing oral hygiene. Oral solutions, sprays or chewable tablets should be used at least 30 minutes before or after administration of the orodispersible tablet.

    Advise patient to avoid exposure to chickenpox, herpes zoster and measles.

    Advise patient to avoid grapefruit products.

    Advise patient to report any signs of fungal infections in the mouth, throat and gullet such as white spots in the mouth and throat and difficulty swallowing.

    Advise patient to report any visual disturbances.

    Advise patient to report any psychological changes, especially suicidal thoughts.

    Side Effects

    Abdominal pain
    Adrenal suppression
    Blurred vision
    Central serous chorioretinopathy
    Contact dermatitis
    Cushing's syndrome
    Dry eyes
    Dry throat
    Duodenal ulcer
    Erosive gastritis
    Gastric ulceration
    Gastroesophageal reflux disease
    Growth retardation (children)
    Increased susceptibility to infection
    Joint pain
    Muscle pain
    Muscle twitch
    Muscle weakness
    Oedema of the lips
    Oesophageal candidiasis
    Oral paraesthesia
    Oropharyngeal candidiasis
    Oropharyngeal pain
    Pseudotumour cerebri
    Psychomotor hyperactivity
    Reduction in serum cortisol levels
    Sensation of foreign body
    Sleep disorders
    Upper abdominal pain
    Wound healing retarded

    Effects on Laboratory Tests

    ACTH stimulation test may show false results (lower values).


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: October 2018

    Reference Sources

    Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 10th edition (2015) ed. Briggs, G., Freeman, R. Wolters Kluwer Health, Philadelphia.

    Summary of Product Characteristics: Jorveza 1mg orodispersible tablets. Dr. Falk Pharma UK Ltd. Revised January 2018.

    Summary of Product Characteristics: Jorveza 0.5mg orodispersible tablets. Dr. Falk Pharma UK Ltd. Revised February 2022.

    NICE Evidence Services Available at: Last accessed: 18 August 2022

    US National Library of Medicine. Toxicology Data Network. Drugs and Lactation Database (LactMed).
    Available at:
    Budesonide. Last revised: 20 July 2020
    Last accessed: 18 August 2022

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.